Alps Advisors Inc. Acquires Shares of 54,314 Clovis Oncology Inc (CLVS)

Alps Advisors Inc. acquired a new stake in Clovis Oncology Inc (NASDAQ:CLVS) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 54,314 shares of the biopharmaceutical company’s stock, valued at approximately $3,693,000.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Orbimed Advisors LLC grew its stake in Clovis Oncology by 13.5% in the third quarter. Orbimed Advisors LLC now owns 2,388,670 shares of the biopharmaceutical company’s stock valued at $196,826,000 after purchasing an additional 284,300 shares during the last quarter. State Street Corp grew its stake in Clovis Oncology by 4.3% in the second quarter. State Street Corp now owns 1,943,480 shares of the biopharmaceutical company’s stock valued at $181,966,000 after purchasing an additional 80,171 shares during the last quarter. Jennison Associates LLC grew its stake in Clovis Oncology by 0.6% in the fourth quarter. Jennison Associates LLC now owns 603,672 shares of the biopharmaceutical company’s stock valued at $41,050,000 after purchasing an additional 3,503 shares during the last quarter. Macquarie Group Ltd. grew its stake in Clovis Oncology by 56.0% in the third quarter. Macquarie Group Ltd. now owns 526,880 shares of the biopharmaceutical company’s stock valued at $43,415,000 after purchasing an additional 189,211 shares during the last quarter. Finally, Westfield Capital Management Co. LP grew its stake in Clovis Oncology by 45.8% in the third quarter. Westfield Capital Management Co. LP now owns 459,470 shares of the biopharmaceutical company’s stock valued at $37,860,000 after purchasing an additional 144,300 shares during the last quarter.

Several equities analysts have issued reports on CLVS shares. ValuEngine upgraded Clovis Oncology from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. BidaskClub upgraded Clovis Oncology from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 9th. Stifel Nicolaus reiterated a “buy” rating and issued a $125.00 target price on shares of Clovis Oncology in a research note on Friday, November 3rd. Oppenheimer reiterated a “hold” rating on shares of Clovis Oncology in a research note on Wednesday, December 20th. Finally, Morgan Stanley cut their target price on Clovis Oncology from $89.00 to $86.00 and set an “overweight” rating on the stock in a research note on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $90.43.

In other news, Director Thorlef Spickschen sold 4,500 shares of the business’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $64.97, for a total transaction of $292,365.00. Following the sale, the director now owns 21,118 shares in the company, valued at $1,372,036.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $63.70, for a total value of $191,100.00. The disclosure for this sale can be found here. Insiders have sold 18,000 shares of company stock worth $1,123,425 in the last 90 days. Insiders own 12.50% of the company’s stock.

Shares of Clovis Oncology Inc (CLVS) opened at $50.12 on Friday. Clovis Oncology Inc has a 52 week low of $45.42 and a 52 week high of $99.45. The firm has a market capitalization of $2,460.00, a PE ratio of -6.05 and a beta of 1.05. The company has a current ratio of 3.19, a quick ratio of 3.16 and a debt-to-equity ratio of 0.94.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/02/09/alps-advisors-inc-acquires-shares-of-54314-clovis-oncology-inc-clvs.html.

Clovis Oncology Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology Inc (NASDAQ:CLVS).

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit